

Biocept Inc. Investor Relations Department 5810 Nancy Ridge Drive San Diego, CA 92121 United States

Visit IR website ☐ Sign-up for Email alerts ☐

1.12
4:00 PM ET Aug 22, 2017
-0.06 ♣ (- 5.085%)
1.12 - 1.20
0.74 - 3.39
202,890

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumorassociated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests perfor... (more)

Stock Performance



Press Releases [View all]

Aug 17, 2017

Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements

Aug 14, 2017

Biocept Enters Into Exclusive Distribution
Agreement with Global Laboratory Product
Supplier VWR

Aug 10, 2017

Biocept Reports Second Quarter 2017 Financial Results

Aug 10, 2017

Biocept Announces Private Placement of \$2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund

Aug 7, 2017

Biocept Executes Preferred Provider
Agreement with Scripps Health Plan
Expanding Patient Coverage for its Liquid
Biopsy Platform

Financials [View all]

Second Quarter Financial Results

Mar 28, 2017

Annual Report (10-K)

Mar 30, 2017

Proxy Statement (DEF 14A)

Aug 14, 2017

Quarterly Report (10-Q)

May 15, 2017

Quarterly Report (10-Q)

Nov 10, 2016

Quarterly Report (10-Q)